CN1080266A - Medical phosphorus 32 series glass microsphere and preparation process thereof - Google Patents
Medical phosphorus 32 series glass microsphere and preparation process thereof Download PDFInfo
- Publication number
- CN1080266A CN1080266A CN 93103780 CN93103780A CN1080266A CN 1080266 A CN1080266 A CN 1080266A CN 93103780 CN93103780 CN 93103780 CN 93103780 A CN93103780 A CN 93103780A CN 1080266 A CN1080266 A CN 1080266A
- Authority
- CN
- China
- Prior art keywords
- phosphorus
- glass
- series glass
- series
- microballoon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011521 glass Substances 0.000 title claims abstract description 69
- OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical class [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000004005 microsphere Substances 0.000 title abstract description 39
- 238000002474 experimental method Methods 0.000 claims abstract description 4
- 229940097886 phosphorus 32 Drugs 0.000 claims description 36
- 239000002245 particle Substances 0.000 claims description 14
- 238000004821 distillation Methods 0.000 claims description 11
- 238000005516 engineering process Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 229910017119 AlPO Inorganic materials 0.000 claims description 5
- 229910017625 MgSiO Inorganic materials 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- NICDRCVJGXLKSF-UHFFFAOYSA-N nitric acid;trihydrochloride Chemical compound Cl.Cl.Cl.O[N+]([O-])=O NICDRCVJGXLKSF-UHFFFAOYSA-N 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 13
- 201000011510 cancer Diseases 0.000 abstract description 11
- 241001465754 Metazoa Species 0.000 abstract description 9
- 238000002844 melting Methods 0.000 abstract description 7
- 230000008018 melting Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract description 5
- 229910052698 phosphorus Inorganic materials 0.000 abstract description 5
- 239000011574 phosphorus Substances 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 3
- AMWVZPDSWLOFKA-UHFFFAOYSA-N phosphanylidynemolybdenum Chemical compound [Mo]#P AMWVZPDSWLOFKA-UHFFFAOYSA-N 0.000 abstract description 3
- 230000002285 radioactive effect Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- QRVXKVFNBYFEOG-UHFFFAOYSA-N phosphanylidynesamarium Chemical compound [Sm]#P QRVXKVFNBYFEOG-UHFFFAOYSA-N 0.000 abstract description 2
- DWDQAMUKGDBIGM-UHFFFAOYSA-N phosphanylidyneyttrium Chemical compound [Y]#P DWDQAMUKGDBIGM-UHFFFAOYSA-N 0.000 abstract description 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 229910052782 aluminium Inorganic materials 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 239000004411 aluminium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000016768 molybdenum Nutrition 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006063 cullet Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 description 2
- 235000019792 magnesium silicate Nutrition 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 2
- 229910052726 zirconium Inorganic materials 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-AKLPVKDBSA-N Molybdenum Mo-99 Chemical compound [99Mo] ZOKXTWBITQBERF-AKLPVKDBSA-N 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- XOXWYYCCVVZUMF-UHFFFAOYSA-N [Y].[P].[Sm] Chemical compound [Y].[P].[Sm] XOXWYYCCVVZUMF-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229950009740 molybdenum mo-99 Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000012736 patent blue V Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000036228 toxication Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Glass Compositions (AREA)
Abstract
The invention discloses a radioactive medical cancer-treating medicament phosphorus 32 series glass microsphere and a preparation process thereof. The phosphorus 32 series glass microspheres are made by melting phosphate and other glass materials which are nontoxic and compatible to human bodies at high temperature into phosphorus glass, phosphorus yttrium glass, phosphorus samarium glass, phosphorus molybdenum glass and the like, and are crushed, made into spheres and subjected to neutron irradiation in a reactor to form the phosphorus 32 series glass microspheres. The phosphorus 32 series glass microspheres are suitable for treating malignant tumor and cancer, and animal experiments and clinical experiments prove that the glass microspheres are safe, reliable and excellent in curative effect, and are ideal new medicines for treating cancer by radioactive internal irradiation.
Description
The present invention relates to medical curing cancer drug of a kind of radioactivity and preparation technology thereof, specifically medical phosphorus 32 P series glass microballoons and preparation technology thereof.
To have the existing vicennial history of research that radioactive solids are used for some cancer knurl of vascular peg stay plug radiation therapy.The once used solids of bibliographical information are for carrying
198The carbon granules of Au contains
90The Y of Y
2O
3Powder is marked with
32P or
90The amberlite lipoid microsphere of Y, the surface scribbles
32P or
90The ceramic microsphere of Y.These particles have good effect to cancer therapy, but also have many shortcomings.As Y
2O
3Powder surface is rough, easily causes the surrounding tissue inflammation, and resin microsphere and ceramic microsphere surface scribble
32P with
90Y easily is discharged in the body from microsphere surface, enters the whole body systemic circulation, and the HUMAN HEALTH tissue is caused unnecessary harm.U.S. Pat P 4789501 disclosed a kind of phosphorus 32 P series glass microballoons and yttrium 90 glass microspheres and preparation technology thereof in 1988, and this invention has avoided above-mentioned microballoon to discharge the disadvantage of diffusion, but still has its weak point.At first, contain chemical elements such as lead, fluorine in the prescription, can cause savings to poison human body.Secondly, also contain elements such as sodium, potassium, zirconium, manganese in the prescription, can produce stronger gamma active element after the activation, kill and wound cancer knurl normal cell on every side easily, unfavorable to HUMAN HEALTH.The 3rd, in the prescription
32The release rate of P does not meet the requirement and the medicine standard of nuclear medicine greater than 0.1%.The 4th, the oxide compound fusing point height of elements such as silicon, aluminium, magnesium brings difficulty to melting in the prescription.The 5th, P
2O
5Easily suction at normal temperatures, and be difficult for and the other materials mixing, it is inhomogeneous to melt the phosphorus glass content that, and the specific activity of phosphorus 32 microballoons of making goes out just inhomogeneous, and P under the high temperature
2O
5Easily distillation loss, melting are also inconvenient.
The object of the present invention is to provide a kind of any poisonous element, easily melting, phosphorus 32 release rates of not containing less than 0.1%, proportion is less than 2.5g/cm
3, be applicable to phosphorus 32 P series glass microballoons and the preparation technology thereof of treatment cancer knurl.
Adopt pure aluminium silicate, Magnesium Silicate q-agent, aluminum phosphate, trimagnesium phosphate as the glass microsphere basic raw material in the present invention's prescription, they are salt, and fusing point is lower than oxide compound, therefore are easy to melting.Therefore elements such as not leaded in the prescription, fluorine do not have the savings toxication to human body.Do not contain elements such as sodium, potassium, zirconium, manganese in the prescription, therefore the activation back does not have very strong gamma activity, and the human normal cell is not had hazardness, and is safe in utilization.Do not use P in the prescription
2O
5, so the raw material fusing time also is easy to mixing, release rate meets medicinal standard.
Phosphorus 32 glass microsphere basic recipes are (weight percent):
Al
2（SiO
3）
355～65%
MgSiO
325～35%
AlPO
410～20%
Y
2O
30～20%
Sm
2O
30～1%
（NH
4）
2MoO
40～1%
For improving the specific activity of phosphorus 32 glass microspheres, except the neutron flux and prolongation irradiation time that improve reactor, can prepare phosphorus, yttrium glass microsphere toward adding yttrium 90 oxide compounds in phosphorus 32 glass microspheres, promptly in basic recipe, add 10～20%Y
2O
3, the content of corresponding minimizing pure aluminium silicate and Magnesium Silicate q-agent.For carrying out experimentation on animals, animal carried out external γ takes pictures or tomography is determined microballoon conduct in animal body or the distribution situation in histoorgan, can be in melting phosphorous or add 0.5～1.0% Sm when containing the glass of yttrium
2O
3Or (NH
4)
2MoO
4Make phosphorus samarium, phosphorus molybdenum microballoon or phosphorus yttrium samarium microballoon, as the γ tracer agent, these microballoons produce gamma-rays behind neutron irradiation in reactor, during experimentation on animals, detect with regard to available gamma camera or ECT, thereby can observe microballoon dynamic change in animal body, distributed areas and anticarcinogenic effect easily.Also can add a spot of Fe respectively
2O
3, CuO, CoO, MnO
2, content is 0.1～1.0%, produces to be used for (as black, green, blue, purple) of all kinds phosphorus 32 P series glass microballoons that cold experiment spike is used.Preparation technology of the present invention is as follows:
To prepare the required component of phosphorus 32 P series glass microballoons mixing by a certain percentage, put into platinum crucible, on high temperature resistance furnace, be heated to 1400～1500 ℃ of fusions, constant temperature 3～5 hours, again crucible is put into the normal temperature redistilled water simultaneously together with Sheng glass, glass is scraped, pour out, 110 ℃ dry-pulverize-filtering out suitable particle size microballoon-chloroazotic acid boils 10～30 minutes-normal temperature second distillation water rinse to neutrality-oven dry-apparatus for making pearl ball system ball-acetone cleaning-redistilled water cleaning-oven dry-screening-20 minutes-second distillation of salt acid soak and is washed to neutrality-oven dry-in muffle furnace and seals in the 4 hours-silica tube of packing into of 400～500 ℃ of constant temperature and make target spare-put irradiation in the reactor-taking-up hydrochloric acid cleaning-second distillation and be washed to neutrality-oven dry packing-high pressure 0.14MPa 30 minutes-finished product of sterilizing.
Utilizing above-mentioned prescription and technology can prepare particle diameter is 10～20 μ m, 20～30 μ m, 45～76 μ m, 100～150 μ m, proportion are various phosphorus 32 P series glass microballoons (phosphorus 32 glass microspheres, phosphorus 32 yttriums 90 glass microspheres, phosphorus 32 samariums 153 glass microspheres, phosphorus 32 molybdenums 99 glass microspheres, phosphorus 32 yttriums 90 samariums 153 glass microspheres) of 2.5g/cm.Particle diameter is but that 10～20 μ m microballoon direct injection are in the cancer tumor tissue, particle diameter is 20～30 μ m, 45～76 μ m microballoons are used for the tumour of arterial perfusion embolism radiation therapy capillary vessel than thin and thicker part position, and particle diameter is that the microballoon of 100～150 μ m is mainly used in experimentation on animals.
Adopt phosphorus 32 P series glass microballoons of prescription of the present invention and prepared not contain any poisonous element, easily melting.Microsphere particle is even, and density is less than 2.5g/cm
3, be easy to perfusion, no bonding under high temperature, high pressure, physiological saline and soda acid soak, there is not distortion, nothing is damaged, serviceability rate 100%.After testing, the phosphorus 32 radioactivity release rates of microballoon meet medical standard less than 0.1%.
Embodiment one
The preparation of phosphorus 32 glass microspheres
1. with 57.9% Al
2(SiO
3)
3, 29% MgSiO
3, 13.1% AlPO
4Abundant mixing, put into platinum crucible, then crucible is placed on and is heated to 1400 ℃ on the high temperature resistance furnace, make the mixture fusion, and fully stir constant temperature 3 hours, mixture in the crucible has become phosphorus glass, then crucible is put into the redistilled water of normal temperature simultaneously together with Sheng glass, make it burst into glass cullet, pour out the back 110 ℃ of oven dry down;
2. with pulverizer phosphorus glass being pulverized is the glass powder of particle diameter 30～76 μ m, filters out the glass powder of desired particle size again with sieve shaker, boils 20 minutes with chloroazotic acid, uses the second distillation water rinse to neutral, 110 ℃ of oven dry then;
3. will dry back glass powder and spray in apparatus for making pearl ball methane-oxygen thermal-flame, fall after the glass powder fusing, just make microballoon, receive with aluminium matter drum then through spraying gun;
4. the microballoon of collecting is washed 3 times with acetone earlier, again with second distillation washing 3 times, 110 ℃ of oven dry down.Filter out the microballoon of required particle diameter (45～76 μ m) with the standard sub-sieve,, be washed to neutrality with second distillation again, 110 ℃ of oven dry down with 0.5mol/l salt acid soak 20 minutes;
5. glass microsphere is put into muffle furnace 400 ℃ of following constant temperature 4 hours;
6. glass microsphere being packed into seals in the silica tube, reinstalls aluminium target tube, makes target spare, is placed on irradiation in the reactor, and specific radioactivity is 54mci/g;
7. the glass microsphere behind the irradiation is taken out from the antimicrobial gloves case, the hydrochloric acid cleaning with 0.5mol/l is washed to neutrality with second distillation again, 110 ℃ of oven dry down;
8. with weighing method microballoon is divided in the vial of 10ml, seals, sterilization took out after 30 minutes under the pressure of 0.14MPa in the autoclave sterilization Sterilizers.
Phosphorus 32 glass microspheres that present embodiment is prepared (particle diameter 45～76 μ m, color beige, proportion 2.3g/cm
3) can be used for local intra-arterial and be poured in radiation therapy cancer knurl in the cancer tumor tissue.
Embodiment two
The preparation of phosphorus 32 yttriums 90 glass microspheres
1. with 60% Al
2(SiO
3)
3, 10% MgSiO
3, 10% AlPO
4With 20% Y
2O
3Mix, put into platinum crucible, then crucible is placed on and is heated to 1450 ℃ on the high temperature resistance furnace, make the mixture fusion, and fully stir constant temperature 4 hours, mixture in the crucible has become phosphorus yttrium glass, then crucible is put into the redistilled water of normal temperature together with glass, make it burst into glass cullet, pour out the back 110 ℃ of oven dry down;
2. identical with embodiment one;
3. identical with embodiment one;
4. identical with embodiment one;
5. glass microsphere is packed in the muffle furnace 450 ℃ of following constant temperature 4 hours;
6. glass microsphere being packed into seals in the silica tube, reinstalls aluminium target tube and makes target spare, is placed on irradiation in the reactor, and yttrium 90 specific radioactivities are about 3.6Ci/g; Phosphorus 32 specific radioactivities are 24mci/g;
7. identical with embodiment one;
8. identical with embodiment one.
Phosphorus 32 yttriums 90 glass microspheres (particle diameter 21～30 μ m, 45～75 μ m, colours white, proportion 2.5g/cm that present embodiment is prepared
3), be used for by arterial perfusion embolism radiation therapy capillary vessel than cancer knurl thick and thin position.
Embodiment three
The preparation of phosphorus 32 molybdenums 99 glass microspheres
1. with 60.8% Al
2(SiO
3)
3, 26.5% MgSiO
3, 11.9% AlPO
4, 0.8% (NH
4)
2MoO
4Mix, put into platinum crucible, then crucible is placed on and is heated to 1500 ℃ on the high temperature resistance furnace, make the mixture fusion, and fully stir constant temperature 5 hours, mixture in the crucible has become the phosphorus molybdenum glass, then crucible is put into the redistilled water of normal temperature together with glass, make it burst into glass cullet, pour out the back 110 ℃ of oven dry down;
2. identical with embodiment one;
3. identical with embodiment one;
4. identical with embodiment one;
5. glass microsphere is put into muffle furnace 500 ℃ of following constant temperature 4 hours;
6. with the glass microsphere sealing, make target spare, be placed on irradiation in the reactor, phosphorus 32 specific radioactivities are 54mci/g; The specific radioactivity of molybdenum 99 is 17mci/g
7. identical with embodiment one;
8. identical with embodiment one.
(particle diameter 100～150 μ m colors are sky-blue to phosphorus 32 molybdenums 99 glass microspheres that present embodiment is prepared, proportion 2.2g/cm
3), can be used for γ spike experimentation on animals.
Phosphorus 32 glass microspheres according to method for preparing; Phosphorus 32 yttriums 90 glass microspheres; Phosphorus 32 molybdenums 99 glass microspheres are respectively applied for the clinical treatment oral carcinoma; Cervical cancer, mammary cancer; And experimentation on animals, curative effect is excellent, does not have any complication and sequela, and is safe and reliable, is a kind of ideal radioactivity internal radiation PTS.
Claims (6)
1, a kind of smooth surface, solid, diameter are 10～20 μ m, 21～30 μ m, and 45～75 μ m, medical phosphorus 32 P series glass microballoons of 76～100 μ m is characterized in that: making phosphorus 32 P series glass microballoon formulation weight per-cents is:
Al
2(SiO
3)
355～65%
MgSiO
325～35%
AlPO
410～20%
Y
2O
30～20%
Sm
2O
30～1%
(NH
4)
2MoO
40～1%
Particles specific weight is less than 2.5g/cm
3, the release rate of phosphorus 32 is less than 0.1%, and specific radioactivity is 20～60mci/g.
2, medical phosphorus 32 P series glass microballoons according to claim 1 is characterized in that also can adding 0.1～1.0% Fe in above-mentioned prescription
2O
3Or CuO, CoO, MnO
2Produce and be used for black, green, blue, purple phosphorus 32 P series glass microballoons that cold experiment spike is used.
3, the preparation technology of medical phosphorus 32 P series glass microballoons described in a kind of claim 1 is characterized in that: raw material is mixed in proportion, through fusion, burst, dry, pulverize, screen, clean, granulation, irradiation, packing, sterilization make.
4, by the described technology of claim 3, it is characterized in that: melt temperature is 1400～1500 ℃, constant temperature 3～5 hours.
5, by the described technology of claim 3, it is characterized in that: the screening back is cleaned and is used chloroazotic acid to boil 10～30 minutes, is washed to neutrality with second distillation again; The back microballoon of granulating uses acetone to clean 3～5 times, is washed to neutrality with second distillation again; Microballoon behind the irradiation uses 0.2～0.6mol/l hydrochloric acid to clean, and is washed to neutrality with second distillation again.
6, by the described technology of claim 3, the pressure that it is characterized in that sterilizing is 0.1～0.2MPa, and sterilization time is 20～40 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93103780A CN1035550C (en) | 1993-04-23 | 1993-04-23 | Medical phosphorus 32 series glass microsphere and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93103780A CN1035550C (en) | 1993-04-23 | 1993-04-23 | Medical phosphorus 32 series glass microsphere and preparation process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1080266A true CN1080266A (en) | 1994-01-05 |
| CN1035550C CN1035550C (en) | 1997-08-06 |
Family
ID=4984788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93103780A Expired - Lifetime CN1035550C (en) | 1993-04-23 | 1993-04-23 | Medical phosphorus 32 series glass microsphere and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1035550C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1798580B (en) * | 2003-04-04 | 2010-10-13 | 生物领域医疗公司 | Microspheres comprising therapeutic and diagnostic radioactive isotopes |
| CN106653134A (en) * | 2017-01-22 | 2017-05-10 | 中国核动力研究设计院 | Preparation method for carrier-free phosphorus 32 |
| CN106683735A (en) * | 2017-01-22 | 2017-05-17 | 中国核动力研究设计院 | Preparation method of carrier phosphor 32 |
| CN112457143A (en) * | 2020-11-27 | 2021-03-09 | 山西江阳兴安民爆器材有限公司 | Emulsion explosive containing tracer marker and preparation method thereof |
| CN114652865A (en) * | 2020-12-23 | 2022-06-24 | 成都纽瑞特医疗科技股份有限公司 | Radioactive glass microsphere injection and preparation method and application thereof |
| CN114699542A (en) * | 2019-09-15 | 2022-07-05 | 合肥启灏医疗科技有限公司 | Radioactive glass microsphere |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4314909A (en) * | 1980-06-30 | 1982-02-09 | Corning Glass Works | Highly refractory glass-ceramics suitable for incorporating radioactive wastes |
| DE3131276C2 (en) * | 1981-08-07 | 1986-02-13 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Process for the solidification of radioactive waste |
| US4789501A (en) * | 1984-11-19 | 1988-12-06 | The Curators Of The University Of Missouri | Glass microspheres |
| JPH03235098A (en) * | 1990-02-10 | 1991-10-21 | Nippon Electric Glass Co Ltd | Vitrification material for vitrification treatment of low level radioactive waste |
| JPH06127973A (en) * | 1992-10-14 | 1994-05-10 | Nippon Electric Glass Co Ltd | Radiation shielding glass |
-
1993
- 1993-04-23 CN CN93103780A patent/CN1035550C/en not_active Expired - Lifetime
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1798580B (en) * | 2003-04-04 | 2010-10-13 | 生物领域医疗公司 | Microspheres comprising therapeutic and diagnostic radioactive isotopes |
| CN106653134A (en) * | 2017-01-22 | 2017-05-10 | 中国核动力研究设计院 | Preparation method for carrier-free phosphorus 32 |
| CN106683735A (en) * | 2017-01-22 | 2017-05-17 | 中国核动力研究设计院 | Preparation method of carrier phosphor 32 |
| CN114699542A (en) * | 2019-09-15 | 2022-07-05 | 合肥启灏医疗科技有限公司 | Radioactive glass microsphere |
| CN114699542B (en) * | 2019-09-15 | 2023-09-15 | 合肥启灏医疗科技有限公司 | Radioactive glass microsphere |
| CN112457143A (en) * | 2020-11-27 | 2021-03-09 | 山西江阳兴安民爆器材有限公司 | Emulsion explosive containing tracer marker and preparation method thereof |
| CN114652865A (en) * | 2020-12-23 | 2022-06-24 | 成都纽瑞特医疗科技股份有限公司 | Radioactive glass microsphere injection and preparation method and application thereof |
| WO2022134408A1 (en) * | 2020-12-23 | 2022-06-30 | 成都纽瑞特医疗科技股份有限公司 | Radioactive glass microsphere injection, preparation method, and use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1035550C (en) | 1997-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU577921B2 (en) | Radioactive biologically compatible glass microspheres | |
| EP1333864B1 (en) | Low density radionuclide-containing particulate material | |
| AU606353B2 (en) | Pharmaceutical formulations | |
| CA2520144C (en) | Microspheres comprising therapeutic and diagnostic radioactive isotopes | |
| CA2181254A1 (en) | Particulate material | |
| FI76254C (en) | Process for the preparation of rapidly decomposing drug presses | |
| EP0955041A2 (en) | Aqueous dispersion useful for the production of coating and binding means for oral solid medicament | |
| CN1035550C (en) | Medical phosphorus 32 series glass microsphere and preparation process thereof | |
| TWI675669B (en) | Radiative microsphere and preparation method thereof | |
| US9539347B2 (en) | Low-density magnesia-alumina-silica (MAS) microparticles for radiotherapy and/or radioimaging | |
| BRPI0806418A2 (en) | oral dosage forms for picoplatin, series of coated granules, process for preparing an oral dosage form for picoplatin and methods of cancer treatments | |
| GB2210790A (en) | Two-layer enteric coated pellet | |
| KR100423859B1 (en) | Vascular Embolic Materials Having Complex Functions | |
| US3720761A (en) | Injectable radio-pharmaceutical scanning agent and preparation | |
| CN101081227B (en) | Composition of diammonium glycyrrhizinate | |
| RU2359702C2 (en) | Way of reception of microspheres labeled with radionuclide | |
| CN107715124A (en) | Medical Y90 carbosphere and preparation method thereof | |
| Wan et al. | Citric acid as a plasticizer for spray-dried microcapsules | |
| JP2025504823A (en) | Gel for radiotherapy and method for preparing same | |
| Ren et al. | Dietary fiber-derived microparticles from microfluidic for drug delivery in treating inflammatory bowel disease | |
| CN118647414A (en) | Radiotherapy gel and preparation method thereof | |
| CN100391442C (en) | Ginseng-monkshood slow-release coating preparation film controlled piller for treating qi asthenia and yang depletion and preparing method thereof | |
| DE2011612B2 (en) | RESORBABLE FAEDS AND FILMS CONTAINING RADIONUCLIDES | |
| CN117602824A (en) | Preparation method of 177Lu glass microspheres and glass powder | |
| JPS58154509A (en) | Preparation of slow-releasing composite |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |
Expiration termination date: 20130423 Granted publication date: 19970806 |